Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

<strong>Background:</strong> Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. <strong&g...

Bibliográfalaš dieđut
Váldodahkkit:	Westwood, S, Baird, AL, Hye, A, Ashton, NJ, Nevado-Holgado, AJ, Anand, SN, Liu, B, Newby, D, Bazenet, C, Kiddle, SJ, Ward, M, Newton, B, Desai, K, Hehir, C, Zanette, M, Galimberti, D, Parnetti, L, Lleó, A, Baker, S, Narayan, VA, Van Der Flier, WM, Scheltens, P, Teunissen, CE, Visser, PJ, Lovestone, S
Materiálatiipa:	Journal article
Almmustuhtton:	Frontiers Media 2018

Geahča maid

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
Dahkki: Sarah Westwood, et al.
Almmustuhtton: (2018-12-01)

The influence of insulin resistance on CSF and plasma biomarkers of Alzheimer’s pathology
Dahkki: Westwood, S, et al.
Almmustuhtton: (2017)

New CSF biomarkers on the block
Dahkki: Charlotte E Teunissen, et al.
Almmustuhtton: (2016-09-01)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
Dahkki: Rosha Babapour Mofrad, et al.
Almmustuhtton: (2019-12-01)

Determining the molecular pathways underlying the protective effect of non-steroidal anti-inflammatory drugs for Alzheimer's disease: A bioinformatics approach
Dahkki: Nevado-Holgado, A, et al.
Almmustuhtton: (2016)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
Dahkki: Eleonora M. Vromen, et al.
Almmustuhtton: (2022-01-01)

Blood-based proteomic biomarkers of Alzheimer’s disease pathology
Dahkki: Baird, A, et al.
Almmustuhtton: (2015)

Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach
Dahkki: Alejo J Nevado-Holgado, et al.
Almmustuhtton: (2017-01-01)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
Dahkki: Betty Marije Tijms, et al.
Almmustuhtton: (2021-08-01)

Establishing cutoff values for visual amyloid positivity in [18F]flutemetamol PET
Dahkki: Yong-Jin Park, et al.
Almmustuhtton: (2025-01-01)

Amyloid-Targeting PET Tracer [18F]Flutemetamol Accumulates in Atherosclerotic Plaques
Dahkki: Sanna Hellberg, et al.
Almmustuhtton: (2019-03-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
Dahkki: Teunissen, C, et al.
Almmustuhtton: (2018)

Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
Dahkki: Lyduine E. Collij, et al.
Almmustuhtton: (2023-11-01)

Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET
Dahkki: Si Eun Kim, et al.
Almmustuhtton: (2020-01-01)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
Dahkki: Eline A. J. Willemse, et al.
Almmustuhtton: (2021-01-01)

Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice.
Dahkki: Stephanie J B Vos, et al.
Almmustuhtton: (2014-01-01)

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
Dahkki: Yanaika S. Hok‐A‐Hin, et al.
Almmustuhtton: (2023-07-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer's disease
Dahkki: Winchester, L, et al.
Almmustuhtton: (2018)

Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods
Dahkki: Mark R. Battle, et al.
Almmustuhtton: (2018-12-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
Dahkki: Charlotte E. Teunissen, et al.
Almmustuhtton: (2018-03-01)

Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.
Dahkki: Vandenberghe, R, et al.
Almmustuhtton: (2013)

Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated
Dahkki: Young-Sil An, et al.
Almmustuhtton: (2021-06-01)

Temporal and anatomical distribution of 18F-flutemetamol uptake in canine brain using positron emission tomography
Dahkki: Taesik Yun, et al.
Almmustuhtton: (2020-01-01)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
Dahkki: Juhan Reimand, et al.
Almmustuhtton: (2019-12-01)

Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly
Dahkki: Westwood, S, et al.
Almmustuhtton: (2016)

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
Dahkki: Vandenberghe, R, et al.
Almmustuhtton: (2010)

Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment
Dahkki: Hugh G. Pemberton, et al.
Almmustuhtton: (2023-05-01)

Automatic lesion detection and segmentation in 18F-flutemetamol positron emission tomography images using deep learning
Dahkki: Chan Ju Ryu
Almmustuhtton: (2022-12-01)

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
Dahkki: Fiona Heeman, et al.
Almmustuhtton: (2019-03-01)

Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank
Dahkki: Cullen, B, et al.
Almmustuhtton: (2018)

Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank
Dahkki: Nevado-Holgado, A, et al.
Almmustuhtton: (2016)

Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and CSF
Dahkki: Winchester, L, et al.
Almmustuhtton: (2022)

18F-flutemetamol PET/CT imaging in the diagnosis of mild cognitive impairment and Alzheimer's disease：a preliminary study
Dahkki: LEI Zhe, et al.
Almmustuhtton: (2022-07-01)

Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
Dahkki: Milos D. Ikonomovic, et al.
Almmustuhtton: (2018-06-01)

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study
Dahkki: Hiroshi Matsuda, et al.
Almmustuhtton: (2021-01-01)

Blood based proteomic biomarkers of Alzheimer’s disease pathology
Dahkki: Alison Louise Baird, et al.
Almmustuhtton: (2015-11-01)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
Dahkki: Carla M. Startin, et al.
Almmustuhtton: (2019-03-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer’s disease
Dahkki: Laura M. Winchester, et al.
Almmustuhtton: (2018-06-01)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
Dahkki: Wesenhagen, KEJ, et al.
Almmustuhtton: (2025)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
Dahkki: Kirsten E. J. Wesenhagen, et al.
Almmustuhtton: (2025-03-01)